TCT-185

Impact of Residual Stenosis of Side Branch on Clinical Outcomes in Patients treated with 1-stent technique for Coronary Bifurcation Lesions

Woo Jin Jang1, Joo-Yong Hah1, Young Bin Song2, Soomuk Choi1
1Samsung Medical Center, Cardiac and Vascular Center, Seoul, Korea, Republic of, 2Samsung Medical Center, Seoul, Republic of, 3Samsung Medical Center, Seoul, Seoul

Background: In coronary bifurcation lesions, little is known about the effect of residual side branch (SB) stenosis after main vessel (MV) stenting on long-term clinical outcomes.

Methods: A total of 2,897 consecutive patients who underwent percutaneous coronary intervention using a drug-eluting stent for a coronary bifurcation lesion with a SB ≥ 2.3 mm were enrolled from 18 centers in South Korea. Of these, we analyzed data from 989 patients who were treated with 1-stent technique for non-left main bifurcation lesions and finally have TIMI flow grade 3 of SB. We compared cardiac death or myocardial infarction according to residual diameter stenosis (DS) of the SB ostium in those patients.

Results: 574 patients have residual SB DS ≥50%, and 989 patients residual SB DS < 50% after the index procedure. During a median follow-up duration of 37 months, patients with residual SB DS ≥50% have a higher incidence of cardiac death or myocardial infarction (1.4 versus 3.3%, p = 0.01) than those with residual SB DS < 50%. Multivariate analysis revealed a higher risk of cardiac death or myocardial infarction (hazard ratio [HR], 2.52; 95% confidence interval [CI], 1.20-5.28; P = 0.02) in the residual SB DS ≥50% group compared to the residual SB DS < 50% group.

Conclusions: Treatments of SB stenosis are associated with high-risk clinical outcomes. Further studies concerning 2-stent technique for SB stenosis may be needed for optimizing clinical outcomes in patients with bifurcation lesions.

TCT-186

Clinical and angiographic outcome of mini-crush stenting for the treatment of true coronary bifurcation lesions

Annamaria Nicolina1, Shahram Moshiri2, Lorenzo Baselli1, Luca Olivotti1, Katia Paone1, Gian Battista Danzi2
1Santa Corona General Hospital, Pietra Ligure, Italy, 2Cardiology, Ospedale Santa Corona, Pietra Ligure, Italy

Background: To evaluate the clinical and angiographic outcome of mini-crush stenting for the treatment of true coronary bifurcation lesions. Percutaneous treatment of coronary bifurcations lesions (CBL) is associated with a low procedural success rate and high incidence of target lesion revascularization (TLR), and stent thrombosis. The provisional single-stenting technique was used in 76 bifurcation lesions. Systematic double stenting technique was applied in 18 bifurcations with double BVS in 13 lesions and mixed BVS-DES in 5 lesions (T-stenting in 11 lesions; Mini-crush technique in 6 lesions; V-stenting technique in one lesion). Meticulous lesion preparation with dedicated devices was needed in 19 lesions. Angiographic success was achieved in 99.0%. At median follow-up of 231 days after the procedure, the overall rates of cardiac death, MI, TLR, TVR and MACE were 0%, 1.2%, 9.5%, 7.1% and 8.2%, respectively. Definite stent thrombosis occurred in one case after discontinuation of dual antiplatelet therapy.

Results: Our conclusions suggest that the treatment with BVS is feasible and effective in a real life setting of bifurcation lesions, despite thick strut (>150 µm) scaffolds and limitation of side-branch closure. Improvements in scaffold design may reduce the need for meticulous lesion predilatation with dedicated devices and increase the spectrum of lesions amenable to treatment with BVS.

TCT-187

Procedural Feasibility and Clinical Efficacy of Bioresorbable Vascular Scaffold in the Treatment of Bifurcation Lesions: Results from a Single Center Experience

Katsumasa Sato1, Azem Latib2, Vasileios F. Panooulas3, Hiroyoshi Kawamoto4, Tadashi Miyazaki1, Tora Nagamune,5 Filippo Figeni1, Alade Chiefo1, Matteo Montorfano4, Mauro Carlin8, Antonio Colombo1
1EMO GVM Centro Cuore Columbus/San Raffaele Scientific Institute, Milan, Italy, 2San Raffaele scientific institute, Milan, Italy

Background: The strut thickness and deliverability of bioresorbable vascular scaffold (BVS) may lead to more challenging for bifurcation lesions. Furthermore, all data concerning BVS feasibility for bifurcation lesions are still limited.

Methods: We analyzed clinical outcome data of patients treated with BVS between May 2012 and May 2014. The measured end-points were cardiac death, follow-up myocardial infarction (MI), target lesion revascularization (TLR), combination of cardiac death, follow-up MI and TVR.

Results: A total of 100 consecutive bifurcation lesions were successfully treated in 85 patients. The mean age was 62.8 ± 11.6 years, and 88.6% were males. Of these patients an angiographic control was scheduled at 9 months.

Conclusions: The dual antiplatelet therapy was maintained in 32 cases and was location of the true SB side branch in all of the cases.

TCT-188

2-year outcomes and angiograms from the bifurcation subgroup of the e-BioMatrix registry

Keith G. Oldroyd1, Jad M. Alhaddad2, jacques berland2, Franz Eberli3, David Hindles-Smith4, David G. Isselbacher1, Franz X. Kleber5, Ian Menon6, Mariano Valdes9, Philip Urban10
1University of Glasgow, Glasgow, United Kingdom, 2Jordon Hospital, Amman, Jordan, 3clinique saint hilaire, rouen, France, 4Triemli Hospital Zurich, Zurich, Switzerland, 5Royal Sussex County Hospital, Brighton, United Kingdom, 6City Center of interventional Cardiology, Moscow, Russian Federation, 7Cardio Centro Berlin, Berlin, Germany, 8Cragavon Area Hospital, Craigavon, United Kingdom, 9Hospital Universitario Virgen de la Arrixaca, Murcia, Spain, 10Hôpital de la Tour, Geneva, Switzerland

Background: PCI of bifurcation lesions is associated with higher rates of restenosis and thrombosis compared to non-bifurcation lesions. In the e-BiC registry we compared the 2 year outcomes of bifurcation and non-bifurcation lesions treated with one or more BioMatrix® or BioMatrix Flex® drug-eluting stents (BES). These stents have an abimensional biodegradable polymer coating that releases Biolimus A9®. The thin strut is fully absorbable and made of implantable material.

Results: A total of 504 patients had PCI of at least one bifurcation lesion, 4968 patients were in the non-bifurcation subgroup. The primary endpoint was Major Adverse Cardiovascular Events (MACE) defined as a composite of cardiac death, myocardial infarction (MI) and clinically-induced target vessel revascularization (ct-TVR) at 12 months. Secondary endpoints were MACE at 30 days, 6 months, 2 years and 3 years, stent thrombosis (ST), major bleeding (MB) and total revascularization rates at 30 days, 6 months, 12 months, 2 years and 3 years. Dual anti-platelet therapy (DAPT) treatment was mandatory for 6 months and recommended up to 12 months.

References: Clinical follow-up at 2 years was obtained in 95.2% of the bifurcation subgroup and 93.7% of the non-bifurcation subgroup. DAPT compliance at 2 years was 30.9% vs. 30.5% respectively (p = NS). A single stent strategy was employed in 79.9% of patients. MACE rates at 2 years were 10.9% vs. 6.4% (p < 0.001) in the bifurcation and non-bifurcation groups, respectively. This difference was driven principally by MI (4.7% vs. 2.2%, p = 0.001) and ct-TVR (8.1% vs. 3.9%, p = 0.001) with no difference in cardiac death (1.2% vs. 1.5%, p = 0.6). Both peri-procedural (1.6% vs. 0.4%, p = 0.002) and spontaneous MIs (2.3% vs. 1.1%, p = 0.2) were